SIGNIFICANT OPERATING AND NONOPERATING ITEMS	9 Months Ended
Oct. 02, 2026
Other Income and Expenses [Abstract]
SIGNIFICANT OPERATING AND NONOPERATING ITEMS	SIGNIFICANT OPERATING AND NONOPERATING ITEMS Other Operating Charges During the three months ended October 2, 2026, the Company recorded other operating charges of $10 million. These charges consisted of $6 million related to North America modernization initiatives and $4 million for the amortization of noncompete agreements related to the BA Sports Nutrition, LLC (“BodyArmor”) acquisition in 2021. During the nine months ended October 2, 2026, the Company recorded other operating charges of $54 million. These charges consisted of $19 million related to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations, $16 million related to North America modernization initiatives, $11 million for the amortization of noncompete agreements related to the BodyArmor acquisition and $8 million related to tax litigation expense. During the three months ended September 26, 2025, the Company recorded other operating charges of $58 million. These charges included $27 million related to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations, $24 million related to the Company’s productivity and reinvestment program, $4 million for the amortization of noncompete agreements related to the BodyArmor acquisition and $3 million related to tax litigation expense. During the nine months ended September 26, 2025, the Company recorded other operating charges of $202 million. These charges consisted of $47 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with our acquisition of fairlife, LLC (“fairlife”) in 2020, which brought the total liability to $6,173 million and was paid in March 2025. Additionally, other operating charges included $63 million related to the Company’s productivity and reinvestment program, $35 million related to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations, $31 million related to the impairment of a trademark that impacted the Latin America operating segment, $11 million for the amortization of noncompete agreements related to the BodyArmor acquisition, $8 million related to tax litigation expense and $7 million of transaction costs related to the refranchising of our bottling operations in certain territories in India. Refer to Note 2 for additional information on our divestiture activities. Refer to Note 9 for additional information on the tax litigation. Refer to Note 15 for additional information on the impairment charge. Other Nonoperating Items Equity Income (Loss) — Net During the three and nine months ended October 2, 2026, the Company recorded net charges of $8 million and $30 million, respectively. During the three and nine months ended September 26, 2025, the Company recorded a net gain of $7 million and a net charge of $21 million, respectively. These amounts represent the Company’s proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees. Other Income (Loss) — Net During the three months ended October 2, 2026, the Company recognized a net gain of $37 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Additionally, the Company recorded charges of $167 million and $25 million for a settlement loss and special termination benefits, respectively, related to a non-U.S. pension plan. The Company also recorded a reduction in the previously recorded impairment charge of $5 million related to our bottling operations in Africa, which are held for sale. This reduction is based on management’s revised estimates. During the nine months ended October 2, 2026, the Company recognized a net gain of $338 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Additionally, the Company recorded charges of $167 million and $25 million for a settlement loss and special termination benefits, respectively, related to a non-U.S. pension plan. The Company also recorded a reduction in the previously recorded impairment charge of $61 million related to our bottling operations in Africa, which are held for sale. This reduction is based on management’s revised estimates. During the three months ended September 26, 2025, the Company recognized a net gain of $151 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities, a charge of $393 million related to certain operations held for sale in Nigeria and a charge of $8 million related to the refranchising of certain bottling operations in Ghana. During the nine months ended September 26, 2025, the Company recognized a gain of $331 million related to the sale of a portion of our ownership interest in CCEP, a net gain of $295 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities and a gain of $102 million related to the refranchising of our bottling operations in certain territories in India. The Company also recorded a charge of $393 million related to certain operations held for sale in Nigeria and recorded other-than-temporary impairment charges of $40 million related to an equity method investee in Latin America and $25 million related to a joint venture in Latin America. Additionally, the Company recorded a charge of $36 million related to the refranchising of certain bottling operations in Ghana, and charges of $25 million and $11 million for special termination benefits and a curtailment loss, respectively, related to non-U.S. pension activity. Refer to Note 2 for additional information on our bottling operations in Africa and our divestiture activities. Refer to Note 4 for additional information on equity and debt securities. Refer to Note 13 for additional information on our pension activities. Refer to Note 15 for additional information on the impairment charges and the bottling operations in Ghana

During the three months ended October 2, 2026, the Company recorded other operating charges of $10 million. These charges consisted of $6 million related to North America modernization initiatives and $4 million for the amortization of noncompete agreements related to the BA Sports Nutrition, LLC (“BodyArmor”) acquisition in 2021.

During the nine months ended October 2, 2026, the Company recorded other operating charges of $54 million. These charges consisted of $19 million related to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations, $16 million related to North America modernization initiatives, $11 million for the amortization of noncompete agreements related to the BodyArmor acquisition and $8 million related to tax litigation expense.

During the three months ended September 26, 2025, the Company recorded other operating charges of $58 million. These charges included $27 million related to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations, $24 million related to the Company’s productivity and reinvestment program, $4 million for the amortization of noncompete agreements related to the BodyArmor acquisition and $3 million related to tax litigation expense.

During the nine months ended September 26, 2025, the Company recorded other operating charges of $202 million. These charges consisted of $47 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with our acquisition of fairlife, LLC (“fairlife”) in 2020, which brought the total liability to $6,173 million and was paid in March 2025. Additionally, other operating charges included $63 million related to the Company’s productivity and reinvestment program, $35 million related to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations, $31 million related to the impairment of a trademark that impacted the Latin America operating segment, $11 million for the amortization of noncompete agreements related to the BodyArmor acquisition, $8 million related to tax litigation expense and $7 million of transaction costs related to the refranchising of our bottling operations in certain territories in India.

During the three and nine months ended October 2, 2026, the Company recorded net charges of $8 million and $30 million, respectively. During the three and nine months ended September 26, 2025, the Company recorded a net gain of $7 million and a net charge of $21 million, respectively. These amounts represent the Company’s proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.

During the three months ended October 2, 2026, the Company recognized a net gain of $37 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Additionally, the Company recorded charges of $167 million and $25 million for a settlement loss and special termination benefits, respectively, related to a non-U.S. pension plan. The Company also recorded a reduction in the previously recorded impairment charge of $5 million related to our bottling operations in Africa, which are held for sale. This reduction is based on management’s revised estimates.

During the nine months ended October 2, 2026, the Company recognized a net gain of $338 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Additionally, the Company recorded charges of $167 million and $25 million for a settlement loss and special termination benefits, respectively, related to a non-U.S. pension plan. The Company also recorded a reduction in the previously recorded impairment charge of $61 million related to our bottling operations in Africa, which are held for sale. This reduction is based on management’s revised estimates.

During the three months ended September 26, 2025, the Company recognized a net gain of $151 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities, a charge of $393 million related to certain operations held for sale in Nigeria and a charge of $8 million related to the refranchising of certain bottling operations in Ghana.

During the nine months ended September 26, 2025, the Company recognized a gain of $331 million related to the sale of a portion of our ownership interest in CCEP, a net gain of $295 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities and a gain of $102 million related to the refranchising of our bottling operations in certain territories in India. The Company also recorded a charge of $393 million related to certain operations held for sale in Nigeria and recorded other-than-temporary impairment charges of $40 million related to an equity method investee in Latin America and $25 million related to a joint venture in Latin America. Additionally, the Company recorded a charge of $36 million related to the refranchising of certain bottling operations in Ghana, and charges of $25 million and $11 million for special termination benefits and a curtailment loss, respectively, related to non-U.S. pension activity.